BIO Europe Hamburg 2019
As every year Atlanpole Biotherapies was present during the BIO Europe, Europe’s largest life science partnering conference, which was held... View Article
3TR: immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases
Autoimmune, inflammatory and allergic diseases are common chronic diseases that significantly affect the wellbeing of millions of people around the... View Article
Radiopharma: an international symposium at Nantes in 2021
After receiving 2,225 submitted abstracts – a new all-time record – also in terms of participation at the EANM congress... View Article
Xenothera receives approval for first in man Kidney Transplant Clinical Trial
Xenothera, member of Atlanpole Biotherapies, announces it has received Czech Republic regulatory agency approval to begin its Phase I/II clinical trial... View Article
[CALL for ABSTRACTS] 4th Nuclear Technologies for Health Symposium- NTHS 2020 | Nantes February 13-14, 2020
Deadline for abstract submission extended to November 27 ! Submit an abstract: here We are pleased to invite you to... View Article
OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®
OSE Immunotherapeutics, member of Atlanpole Biotherapies, announce that new clinical and preclinical data on its products in immuno-oncology-Tedopi®,BI 765063 (OSE-172)... View Article
Porsolt increases its drug discovery service capabilities with the recent expansion of its research facility
Laval, France, 3rd September 2019 – Porsolt SAS, a long established preclinical screening, efficacy, and safety CRO, has completed a... View Article
InFlectis BioScience announces favorable results for IFB-088 Phase 1 Single Ascending Dose clinical trial
IFB-088 observed to have a favorable safety, tolerability and pharmacokinetic profile in the Phase 1 trial IFB-088 is advancing into... View Article
In-Cell-Art announces the publication in Nature Biomedical Engineering of a Nanotaxi® for messenger RNA vaccin
In-Cell-Art (ICA), a biotechnology company specialized in nanocarrier technologies named Nanotaxi® for unlocking the promise of nucleic acids to treat... View Article
Premium ADCC project, positive results for Clean Cells
An example of an innovative product placed on the market thanks to a collaborative innovation project financed by the Single... View Article